The efficacy and safety of standardized dust mite allergen subcutaneous immunotherapy in children with allergic rhinitis during treatment
10.3760/cma.j.cn115330-20230331-00146
- VernacularTitle:标准化尘螨过敏原SCIT对儿童AR患者治疗期间的疗效及安全性分析
- Author:
Xuan YUAN
1
;
Shaobing XIE
;
Hua ZHANG
;
Junyi ZHANG
;
Fengjun WANG
;
Yongzhen LIU
;
Lai MENG
;
Wei ZHONG
;
Weihong JIANG
;
Zhihai XIE
Author Information
1. 中南大学湘雅医院耳鼻咽喉头颈外科 耳鼻咽喉科重大疾病研究湖南省重点实验室，长沙 410008
- Keywords:
Allergic rhinitis;
Children;
Subcutaneous immunotherapy;
Efficacy;
Safety
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2023;58(9):878-884
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of standardized dust mite allergen subcutaneous immunotherapy (SCIT) in children with allergic rhinitis (AR) during treatment.Methods:A total of 283 children with AR diagnosed with definite dust mite allergy and completed 2 to 3 years of SCIT who attended the Department of Otorhinolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, from August 2019 to October 2021 were included, including 205 males and 78 females, with a mean age of 10.8 years. The total nasal symptoms score (TNSS), symptom medication score (SMS), rhinoconjunctivitis quality of life questionnaire (RQLQ) and visual analogue scale (VAS) before and after 2 to 3 years′ treatment were recorded, and the differences before and after treatment were compared. Adverse reactions during SCIT were recorded to evaluate its safety. SPSS 22.0 software was used for statistical analysis.Results:The overall effectiveness rate during SCIT in 283 children with AR was 89.4% (253/283). Compared with baseline, all symptom scores, medication scores and quality of life scores were significantly lower after 2 to 3 years of SCIT (all P<0.05). Further group comparisons showed positive efficacy in patients with different clinical characteristics, including age, gender, smoking status, family history of AR, symptom severity, mono-or poly-allergy, and second immunization, with no statistically significant differences between groups (all P>0.05). A total of 12 735 injections were administered during the SCIT, and a total of 213 (1.67%) injections of local adverse reactions occurred, mainly in the initial treatment phase, and the diameter of the local air mass was mostly 5 to 20 mm; 71 (0.56%) injections of systemic adverse reactions occurred, mainly in the initial treatment phase, and most of them were grade 1 reactions with no serious systemic adverse reaction such as shock. Conclusion:Standardized dust mite SCIT has a good safety profile and definite efficacy in treating AR children with different clinical characteristics. It can significantly improve all symptoms, reduce the use of symptomatic drugs and improve their quality of life.
